Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis.

Zahra GoudarziMehrdad MostafaviMahmood SalesiMojtaba JafariIman MirianAmir Hashemi MeshkiniKhosro KeshavarzYounes Ghasemi

Published in: Cost effectiveness and resource allocation : C/E (2023)

According to the results of this study, Everolimus could be related to an increase of OS versus Temsirolimus as a second line treatment of ORCC patients.

Keyphrases

metastatic renal cell carcinoma
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
patient reported outcomes
combination therapy
patient reported